Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.

Current Report (Amendment) (Form 8-K/A | Period ending 2024-08-20)

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Reviva Pharmaceuticals Holdi (RVPH US)

Current Report (Amendment) (Form 8-K/A | Period ending 2024-08-20)

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2024-08-20)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-14)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)